Femitas Email Formats

Biotechnology Research • • 1-10 Employees

Key Contact at Femitas

Glenn Cornett

Co-Founder, Board member

Company overview

Headquarters	XX
NAICS	541714
Employees	1-10

About Femitas

Femitas is developing a new class of drugs for menopausal aging and maternal health (preeclampsia, gestational hypertension). Our lead drug has placebo-controlled clinical proof of concept vs. hypertension in women > 60 and RWE (real-world experience) trial demonstrating >60% reduction in hot flashes. We have extensive mechanistic data supporting relevance for sexual function in menopausal aging. Relevance in all of these applications (hypertension, hot flashes, and sexual function) is underpinned by the drug's three-fold activity vs. cardiovascular phenomena that affect women more than men after age 60: A) Endothelial dysfunction B) Sympathetic nervous system (SNS) activation C) Salt-sensitive hypertension.